RPL11 Antibody

What is RPL11 and why is it significant in cellular research?

RPL11 (Ribosomal Protein L11) is one of approximately 80 mammalian ribosomal proteins, with a molecular weight of approximately 20 kDa. This protein plays crucial roles beyond its structural function in ribosomes. RPL11 is particularly significant because it binds to 5S ribosomal RNA and is required for rRNA maturation and formation of the 60S ribosomal subunit . More importantly, RPL11 was the first ribosomal protein identified to interact with and inhibit the E3 ligase function of MDM2, leading to p53 stabilization and activation . This connection to the p53 pathway makes RPL11 a significant research target in studies related to ribosome biogenesis, cellular stress responses, and certain pathological conditions including Diamond-Blackfan anemia and potentially cancer.

Which experimental applications can RPL11 antibodies be used for?

RPL11 antibodies have been validated for multiple experimental applications, with varying recommended dilutions:

It's important to note that optimal dilutions are sample-dependent, and researchers should titrate the antibody in each specific testing system to obtain optimal results .

How should RPL11 antibodies be stored and handled to maintain reactivity?

For optimal performance and longevity of RPL11 antibodies:

• Store at -20°C in the recommended buffer (typically PBS with 0.02% sodium azide and 50% glycerol pH 7.3)

• Most formulations are stable for one year after shipment when stored properly

• Aliquoting is generally unnecessary for -20°C storage with the glycerol formulation

• Avoid repeated freeze-thaw cycles

• Some preparations (20μl sizes) may contain 0.1% BSA as a stabilizer

• When working with the antibody, maintain cold chain whenever possible and return to -20°C promptly after use

• Follow manufacturer's specific recommendations, as storage conditions may vary slightly between products

What are the key considerations for optimizing Western blot protocols with RPL11 antibodies?

Optimizing Western blot protocols for RPL11 detection requires attention to several methodological details:

How can I validate the specificity of an RPL11 antibody in my experimental system?

Validating antibody specificity is critical for generating reliable results. For RPL11 antibodies, consider these validation approaches:

• Positive and negative controls:

  • Positive controls: Use tissues/cells known to express RPL11 (e.g., human liver tissue, BxPC-3 cells)

  • Negative controls: Use RPL11 knockout or knockdown systems

• Multiple antibody validation: Use antibodies from different sources or that recognize different epitopes of RPL11.

• Immunoprecipitation followed by mass spectrometry: This can confirm that the antibody is pulling down RPL11 specifically.

• Band size verification: Confirm that the detected band appears at the expected molecular weight of 20 kDa .

• RNA interference: Compare antibody reactivity in samples with normal and reduced RPL11 levels via siRNA or shRNA approaches .

• Peptide competition assay: Pre-incubation of the antibody with the immunizing peptide should abolish specific signals.

• Cross-reactivity testing: If working with non-validated species, test for cross-reactivity using sequence homology analysis and empirical testing.

How can RPL11 antibodies be used to investigate the RP-MDM2-p53 pathway in ribosomal stress models?

RPL11 plays a central role in ribosomal stress signaling through the RP-MDM2-p53 pathway. Here's how to use RPL11 antibodies for investigating this pathway:

• Co-immunoprecipitation studies: Use RPL11 antibodies to pull down protein complexes and probe for MDM2, p53, and other interacting partners like p14ARF/p19Arf . This approach can reveal how different stressors affect complex formation.

• Chromatin immunoprecipitation (ChIP): Determine if RPL11 associates with chromatin at p53-regulated gene promoters as part of transcriptional regulation complexes.

• Dual immunofluorescence: Visualize colocalization of RPL11 with MDM2, p53, and nucleolar markers under different stress conditions.

• Analysis of posttranslational modifications: Investigate how ribosomal stress affects RPL11 modifications that might regulate its interaction with MDM2.

• Ribosomal stress induction protocols: Compare RPL11 localization and MDM2 binding before and after treatments with:

  • Actinomycin D (low dose)

  • 5-Fluorouracil

  • Mycophenolic acid

  • Nutrient starvation

• Polysome profiling: Couple with RPL11 immunoblotting to analyze redistribution of RPL11 from ribosomes to nucleoplasm under stress conditions.

• Knockout/knockdown recovery experiments: Use RPL11 antibodies to confirm restoration of signaling in rescue experiments.

Research has shown that of all MDM2-binding ribosomal proteins, RPL11 appears particularly important for p53 regulation, as it is protected from proteasomal degradation upon ribosomal biogenesis stress while many other MDM2-binding RPs are degraded .

What methodological approaches can be used to study RPL11's role in erythropoiesis and hematopoietic disorders?

Given RPL11's critical role in erythropoiesis and its implications in disorders like Diamond-Blackfan anemia, these methodological approaches are valuable:

• Flow cytometry analysis of erythroid differentiation:

  • Use CD71 and Ter119 markers along with RPL11 antibodies to track expression during differentiation stages

  • Analyze cell cycle distribution in sorted populations (particularly important as RPL11 haploinsufficiency induces G1 cell cycle arrest specifically in erythroid lineage cells)

• Colony-forming assays:

  • Compare BFU-E and CFU-E colony formation in control vs. RPL11-deficient samples

  • Correlate colony numbers with RPL11 expression levels quantified by Western blot

• Immunohistochemistry (IHC) of bone marrow and spleen sections:

  • Analyze RPL11 expression in hematopoietic tissues

  • Look for correlations between RPL11 levels and p53 activation markers

• In vitro erythroid differentiation systems:

  • Monitor RPL11 expression during differentiation using Western blot

  • Correlate with hemoglobinization and erythroid marker expression

• p53 pathway analysis in erythroid progenitors:

  • Multiplex staining for RPL11, p53, and p21 (Cdkn1a)

  • Analyze activation of p53 target genes in sorted populations

• Polysome profiling in erythroid cells:

  • Assess ribosome assembly and protein synthesis rates in relation to RPL11 levels

  • Study specific effects on translation of erythroid-specific mRNAs

RPL11 haploinsufficiency leads to activation of p53 specifically in hematopoietic tissues and impedes erythroid precursor differentiation, resulting in insufficient red blood cell development . Understanding these mechanisms can provide insights into Diamond-Blackfan anemia and other ribosomopathies.

How can I troubleshoot nucleolar staining patterns with RPL11 antibodies in immunofluorescence experiments?

Nucleolar staining with RPL11 antibodies can be challenging due to the dense structure of nucleoli and RPL11's dynamic localization. Here are troubleshooting strategies:

• Fixation optimization:

  • Compare 4% paraformaldehyde (10-15 minutes) versus methanol-acetone (1:1, -20°C, 10 minutes)

  • Nucleolar proteins often show different accessibility depending on fixation method

• Permeabilization assessment:

  • Test different detergents (0.1-0.5% Triton X-100, 0.05% Saponin)

  • Permeabilization time may need adjustment for nucleolar access

• Antigen retrieval methods:

  • For tissue sections, try citrate buffer (pH 6.0) or TE buffer (pH 9.0)

  • For cultured cells, brief treatment with dilute HCl can improve nucleolar antigen accessibility

• Antibody dilution range:

  • Test broader dilution range than recommended (1:5 to 1:200) as nucleolar staining may require higher concentrations

• Blocking optimization:

  • Use 5-10% normal serum from the same species as the secondary antibody

  • Add 0.1-0.3% Triton X-100 to blocking solution for better penetration

• Co-staining with nucleolar markers:

  • Use established nucleolar markers (fibrillarin, nucleolin) to confirm localization

  • In ribosomal stress, RPL11 may relocalize outside nucleoli - this is biologically significant, not a technical artifact

• Sample-specific considerations:

  • Observe that MEF cells with RPL11 deletion show malformed and heavily fused nucleoli

  • Compare nucleolar morphology across different cell types and conditions

• Sequential immunostaining:

  • If co-staining presents challenges, consider sequential staining protocols

  • Document and analyze changes in RPL11 localization under different stress conditions

How should I analyze and interpret changes in RPL11 expression levels in response to ribosomal stress?

When analyzing changes in RPL11 expression during ribosomal stress:

• Distinguish between transcriptional and post-transcriptional effects:

  • Compare protein levels (Western blot) with mRNA levels (qRT-PCR)

  • Research shows RPL11 deletion reduced expression of other RPs at protein level but not mRNA level, indicating a posttranscriptional effect

• Consider compartment-specific changes:

  • Nucleolar versus nucleoplasmic versus cytoplasmic fractions may show different patterns

  • Nuclear-cytoplasmic fractionation followed by Western blot can reveal redistribution

• Temporal dynamics:

  • Establish a time-course to capture early, intermediate, and late responses

  • RPL11 stabilization often precedes p53 accumulation

• Correlation with p53 pathway activation:

  • Measure p53 levels, phosphorylation status, and target gene expression

  • Analyze p21 (Cdkn1a) as a p53 target gene marker

• Context-specific interpretation:

  • Tissue-specific differences exist - RPL11 heterozygous deletion activates p53 predominantly in hematopoietic tissues

  • Cell type-specific responses may vary significantly

• Quantification methods:

  • Use digital imaging software with appropriate controls

  • Consider ratiometric analysis (e.g., RPL11/p53 ratio)

• Response to intervention:

  • Analyze how genetic manipulations (e.g., p53 dosage reduction) affect the phenotype

  • Test pharmacological modulators of the pathway

What controls are essential when using RPL11 antibodies to study protein-protein interactions via co-immunoprecipitation?

For rigorous co-immunoprecipitation studies with RPL11 antibodies:

• Input controls:

  • Always include input samples (pre-IP lysate, typically 5-10%)

  • Analyze both target and potential interacting proteins in input

• Negative controls:

  • IgG control from same species as the RPL11 antibody

  • Ideally, include samples with RPL11 knockdown or knockout

  • Consider using cells treated with or without ribosomal stress inducers

• Reciprocal co-IP:

  • Confirm interactions by performing IP with antibodies against predicted partners (e.g., MDM2, p53)

  • Probe for RPL11 in these reciprocal IPs

• Blocking peptide controls:

  • Pre-incubate antibody with immunizing peptide to confirm specificity

  • The blocked antibody should fail to immunoprecipitate the target

• Validation of interactions:

  • Use antibodies against different epitopes of the same protein

  • Consider GST-pulldown or proximity ligation assays as orthogonal methods

• RNase treatment controls:

  • Some RPL11 interactions may be RNA-dependent

  • Include samples with RNase treatment to distinguish direct protein-protein interactions

• Detergent sensitivity:

  • Test multiple lysis conditions as some interactions may be sensitive to detergent type and concentration

  • Compare RIPA buffer with milder NP-40 or Triton X-100 buffers

• Subcellular fraction controls:

  • When possible, perform IPs from nuclear, nucleolar, and cytoplasmic fractions separately

  • This can reveal compartment-specific interactions

Research has established that RPL11 interacts with p14ARF (p19Arf in mouse) to augment p53 activation during ribosomal stress , and that RPL11, but not other RPs, promotes MDM2-mediated MDMX polyubiquitination and degradation . These specific interactions make proper controls essential.

How can RPL11 antibodies be used in proximity ligation assays to visualize protein interactions in situ?

Proximity Ligation Assay (PLA) is a powerful technique for visualizing protein-protein interactions within cells with high sensitivity and specificity. For RPL11 interactions:

• Experimental design for RPL11-MDM2 interaction:

  • Use primary antibodies from different species (e.g., rabbit anti-RPL11 and mouse anti-MDM2)

  • Optimize fixation for both nucleolar and nucleoplasmic preservation

  • Compare normal conditions versus ribosomal stress conditions

• Controls for PLA specificity:

  • Single antibody controls (omit one primary antibody)

  • Non-interacting protein pairs as negative controls

  • Known interacting proteins as positive controls

  • RPL11 knockdown to confirm signal specificity

• Multiplex PLA with immunofluorescence:

  • Combine PLA (e.g., RPL11-MDM2) with standard IF for nucleolar markers

  • This approach can show where in the cell these interactions occur

• Quantification approaches:

  • Count PLA foci per cell or per compartment

  • Measure size and intensity of PLA signals

  • Compare between different cell populations or treatments

• Applications to study nucleolar stress response:

  • Visualize dynamic changes in RPL11 interactions during nucleolar stress

  • Track relocalization of RPL11 from nucleolus to nucleoplasm

  • Correlate with p53 activation markers

• Tissue-specific interactions:

  • Apply PLA to tissue sections to examine RPL11 interactions in vivo

  • Particularly useful for studying hematopoietic tissues where RPL11 haploinsufficiency shows strongest effects

• Technical considerations:

  • Optimal primary antibody dilutions for PLA are typically higher than for standard IF

  • Signal-to-noise ratio may require extensive optimization

What methodological approaches can investigate the role of RPL11 in global protein synthesis and ribosome biogenesis?

To study RPL11's role in protein synthesis and ribosome biogenesis:

• Polysome profiling:

  • Analyze 40S, 60S, 80S and polysome peaks with and without RPL11 depletion

  • RPL11 deletion prevents maturation of 60S large ribosomal subunit and assemblage of 80S ribosome and polysomes

  • Quantify differences in peak heights and areas across conditions

• Global protein synthesis measurement:

  • Use metabolic labeling with [35S]-methionine to quantify translation rates

  • Apply SUnSET (Surface Sensing of Translation) using puromycin incorporation

  • RPL11 deletion reduces global protein synthesis

• Ribosome biogenesis analysis:

  • Pulse-chase experiments with 32P-orthophosphate to track rRNA processing

  • Northern blotting for pre-rRNA intermediates

  • Fluorescence in situ hybridization for rRNA localization

• Nucleolar integrity assessment:

  • Use RPL11 antibodies with other nucleolar markers to study nucleolar morphology

  • MEF cells with RPL11 deletion show malformed and heavily fused nucleoli

• Nascent RNA and protein synthesis imaging:

  • EU (5-ethynyl uridine) labeling for nascent RNA visualization

  • O-propargyl-puromycin (OPP) labeling for nascent protein synthesis

  • Co-staining with RPL11 antibodies

• RNA-seq and Ribo-seq analyses:

  • Compare transcriptome and translatome profiles in control versus RPL11-depleted cells

  • Identify specific mRNAs most affected by RPL11 deficiency

• Mass spectrometry approaches:

  • Quantitative proteomics to measure changes in ribosomal proteins

  • RPL11 deletion reduces expression of other RPs at protein but not mRNA level

How can I design experiments to distinguish between RPL11's ribosomal and extraribosomal functions?

Distinguishing between RPL11's canonical ribosomal role and its extraribosomal functions (particularly in p53 regulation) requires careful experimental design:

• Structure-function analysis:

  • Generate mutants that selectively disrupt specific interactions

  • Test mutants that can bind MDM2 but not incorporate into ribosomes

  • Analyze rescue capabilities of different mutants in RPL11-depleted systems

• Cell fractionation approaches:

  • Compare RPL11 in ribosomal, nucleolar, nucleoplasmic, and cytosolic fractions

  • Track redistribution upon ribosomal stress

  • Identify fraction-specific interaction partners

• Selective depletion strategies:

  • Design siRNAs targeting RPL11 mRNA regions affecting translation of specific isoforms

  • Use CRISPR-Cas9 to introduce subtle mutations that affect specific functions

• Ribosome profiling with selective perturbation:

  • Compare ribosome occupancy profiles between wild-type and RPL11 mutant cells

  • Analyze specific mRNA translation affected by RPL11 deficiency

• Temporal separation of functions:

  • Use rapid induction systems to distinguish immediate versus delayed effects

  • Immediate effects likely represent extraribosomal functions, while delayed effects may reflect ribosome biogenesis defects

• Tissue-specific analysis:

  • Compare tissues with different sensitivities to RPL11 depletion

  • Hematopoietic tissues show particular sensitivity to RPL11 haploinsufficiency

• Paired knockdown approach:

  • Compare effects of RPL11 depletion alone versus RPL11 + p53 co-depletion

  • Effects rescued by p53 depletion likely represent extraribosomal functions

• Analysis of RPL11 in Diamond-Blackfan anemia:

  • Study patient-derived cells carrying RPL11 mutations

  • Determine if mutations differentially affect ribosomal versus extraribosomal functions

What emerging technologies might enhance the utility of RPL11 antibodies in research?

Several emerging technologies have potential to expand RPL11 antibody applications:

• Super-resolution microscopy:

  • STORM, PALM, and STED microscopy can reveal RPL11 distribution within nucleolar subcompartments

  • Track dynamic changes during stress responses at nanoscale resolution

• CRISPR epitope tagging:

  • Endogenous tagging of RPL11 allows live-cell imaging without overexpression artifacts

  • Can be combined with antibodies for comparison and validation

• Antibody engineering approaches:

  • Single-domain antibodies (nanobodies) for improved nucleolar penetration

  • Recombinant antibody fragments for super-resolution microscopy

• Mass cytometry (CyTOF):

  • Metal-conjugated RPL11 antibodies for high-dimensional analysis of hematopoietic cells

  • Simultaneously measure RPL11 with dozens of other markers

• Spatial transcriptomics integration:

  • Combine RPL11 immunostaining with spatial transcriptomics

  • Correlate RPL11 protein levels with local transcriptional responses

• Single-cell proteomics:

  • Apply RPL11 antibodies in emerging single-cell proteomics workflows

  • Correlate with single-cell RNA-seq data

• In vivo antibody-based biosensors:

  • Develop conformational antibodies that selectively recognize "free" versus ribosome-incorporated RPL11

  • Create biosensors to monitor RPL11-MDM2 interactions in real-time

• Proximity-dependent biotinylation:

  • Combine with RPL11 antibodies to validate interaction partners identified through BioID or APEX approaches

  • Map the dynamic RPL11 interactome under various stress conditions

How can RPL11 antibodies contribute to understanding and treating Diamond-Blackfan anemia and other ribosomopathies?

RPL11 antibodies can advance both basic understanding and clinical approaches to ribosomopathies:

• Diagnostic applications:

  • Develop immunoassays to measure RPL11 levels in patient samples

  • Assess correlations between RPL11 levels and disease severity

• Patient-derived xenograft models:

  • Use RPL11 antibodies to characterize protein expression in PDX models

  • Test therapeutic approaches targeting the p53 pathway

• Drug screening approaches:

  • Develop high-content screening assays using RPL11 antibodies

  • Identify compounds that modulate RPL11-MDM2 interaction or stabilize RPL11

• Genotype-phenotype correlations:

  • Compare RPL11 expression and localization across patients with different mutations

  • Correlate with hematological parameters and treatment responses

• Monitoring therapeutic responses:

  • Use RPL11 antibodies to track molecular responses to treatments

  • Assess normalization of nucleolar structure and function

• Targeted protein degradation approaches:

  • Develop PROTACs or molecular glues targeting aberrant RPL11 complexes

  • Use RPL11 antibodies to monitor degradation efficacy

• Gene therapy monitoring:

  • In gene therapy approaches for RPL11-deficient Diamond-Blackfan anemia

  • Track restoration of normal RPL11 expression levels and localization

• Biomarker development:

  • Identify RPL11-associated biomarkers of disease progression or treatment response

  • Develop minimally invasive monitoring strategies

Mutations in the RPL11 gene have been found in patients with Diamond-Blackfan anemia , and understanding the molecular mechanisms through which RPL11 haploinsufficiency leads to anemia can provide insights for developing targeted therapies.